TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07391644: A First-in-Human, Open-Label, Multicenter, Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of JSKN027 in Patients With Advanced Malignant Solid Tumors

Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 250 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07391644 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07391644 Rescue Dossier →